Market watchers predict more mega-M&A

Think the pharma megamerger is done ... over ... finito? Think again. Some analysts and money men are saying that the drug industry is still ripe for consolidation. After all, no one company has more than 8 percent of the global market for prescription drugs.

And given that market shares are in the single digits, says noted venture capitalist G. Steven Burrill of Burrill & Co., "That would generally indicate that we have a ways to go on consolidation." Yep, says Simon King, a senior analyst at Datamonitor. He told Chemical & Engineering News, "There's definitely a couple of large M&A events left in Big Pharma."

Large M&A events? We can almost hear the market-watchers speculating now. Who might it be? Eli Lilly? Bristol-Myers Squibb? Send us your ideas in the comments.

- get the news from C&E

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.